The groundbreaking success of Sildenafil undeniably reshaped the pharmaceutical landscape, but betting in companies primarily reliant on unbranded versions presents a complex picture. Despite early profits were substantial, the expiration of patents and the rise of cheaper alternatives have diminished sales. Therefore, a thorough analysis of presen